𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Drug-Loaded Superparamagnetic Iron Oxide Nanoparticles for Combined Cancer Imaging and Therapy In Vivo

✍ Scribed by Mi Kyung Yu; Yong Yeon Jeong; Jinho Park; Sangjin Park; Jin Woong Kim; Jung Jun Min; Kyuwon Kim; Sangyong Jon

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
560 KB
Volume
120
Category
Article
ISSN
0044-8249

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Superparamagnetic Iron Oxide Nanoparticl
Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy
✍ Andrew Z. Wang; Vaishali Bagalkot; Christophoros C. Vasilliou; Frank Gu; Frank A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB

Over the past two decades, molecular targeted diagnostic and therapeutic agents have dramatically improved cancer diagnosis and treatment. [1][2][3][4][5][6][7][8] Targeting allows the preferential delivery of therapeutic, diagnostic, or imaging agents to the intended site. Advances in nanotechnolog

Superparamagnetic iron oxide nanoparticl
Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo
✍ Chang-Moon Lee; Hwan-Jeong Jeong; Eun-Mi Kim; Dong Wook Kim; Seok Tae Lim; Hyoun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB

## Abstract Hepatocyte‐specific targeting agents are useful for evaluation of the hepatocytic function and the monitoring of disease progress. Superparamagnetic iron oxide nanoparticles (SPION) bearing terminal galactose groups exhibit a high affinity for the asialoglycoprotein receptor on the hepa

CMR 2005: 3.06: PEGylated and fluorescen
CMR 2005: 3.06: PEGylated and fluorescent superparamagnetic liposomes provide a promising tool for combining in vivo imaging and therapy
✍ S. Lesieur; M.S. Martina; V. Plassat; J.P. Fortin; C. Rivière; G. Barratt; C. Mé 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Rationale and Objectives: Cationic liposomes are a tool for targeted delivery of diagnostic and therapeutic compounds to the neovasculature around a solid tumor, due to a preferential binding with activated endothelial cells (1). On this basis, Medigene is developing cationic nanoparticulate carrier